Novo Nordisk's Ozempic successor disappointed Wall Street again

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time.Read more...

Related Posts

The 5 best states in America for women — and the 5 worst

Mar 3, 2025  0

The Dow plunges up to 700 points because now Trump’s tr...

Mar 4, 2025  0

America had the most new multimillionaires in 2024. Her...

Mar 5, 2025  0

Comments

Name

Email

Comment

Post Comment